- Home
- ADAP vs ANL Comparison
ADAP vs ANL Comparison
Compare ADAP & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- ANL
- Stock Information
- Founded
- ADAP 2008
- ANL 2004
- Country
- ADAP United Kingdom
- ANL Cayman Islands
- Employees
- ADAP N/A
- ANL N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- ADAP Health Care
- ANL
- Exchange
- ADAP Nasdaq
- ANL Nasdaq
- Market Cap
- ADAP 71.6M
- ANL 81.9M
- IPO Year
- ADAP 2015
- ANL 2023
- Fundamental
- Price
- ADAP $0.20
- ANL $2.05
- Analyst Decision
- ADAP Strong Buy
- ANL Strong Buy
- Analyst Count
- ADAP 5
- ANL 2
- Target Price
- ADAP $1.93
- ANL $9.00
- AVG Volume (30 Days)
- ADAP 2.5M
- ANL 6.8K
- Earning Date
- ADAP 03-20-2025
- ANL 04-08-2025
- Dividend Yield
- ADAP N/A
- ANL N/A
- EPS Growth
- ADAP N/A
- ANL N/A
- EPS
- ADAP N/A
- ANL N/A
- Revenue
- ADAP $178,032,000.00
- ANL $5,000,000.00
- Revenue This Year
- ADAP N/A
- ANL N/A
- Revenue Next Year
- ADAP $56.87
- ANL N/A
- P/E Ratio
- ADAP N/A
- ANL N/A
- Revenue Growth
- ADAP 195.34
- ANL N/A
- 52 Week Low
- ADAP $0.20
- ANL $1.85
- 52 Week High
- ADAP $1.55
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- ADAP 13.88
- ANL 38.59
- Support Level
- ADAP $0.26
- ANL $2.02
- Resistance Level
- ADAP $0.47
- ANL $2.49
- Average True Range (ATR)
- ADAP 0.04
- ANL 0.14
- MACD
- ADAP -0.02
- ANL -0.02
- Stochastic Oscillator
- ADAP 1.53
- ANL 7.22
Stock Price Comparison Chart: ADAP vs ANL
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.